The Dunning model

Prostate

Volumn 43, Issue 4, 2000, Pages 295-302

  Tennant, Thelma R ^a   Kim, Hyung ^a   Sokoloff, Mitchell ^a   Rinker Schaeffer, Carrie W ^a  

^a UNIVERSITY OF CHICAGO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANIMAL CELL; ANIMAL TISSUE; ARTICLE; CANCER HORMONE THERAPY; CANCER IMMUNOTHERAPY; HISTOPATHOLOGY; HISTORY OF MEDICINE; MALE; NONHUMAN; PRIORITY JOURNAL; PROSTATE CANCER; RAT;

ANIMALS; DISEASE MODELS, ANIMAL; HUMANS; MALE; MODELS, BIOLOGICAL; PROSTATIC NEOPLASMS; TUMOR CELLS, CULTURED;

EID: 0034213355     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/1097-0045(20000601)43:4<295::AID-PROS9>3.0.CO;2-W     Document Type: Article

References (66)

1. Isaacs JT, Heston WD, Weissman RM, Coffey DS. Animal models of the hormone-sensitive and -insensitive prostatic adenocarcinomas, Dunning R-3327-H, R-3327-H1, and R-3327-AT. Cancer Res 1978;38:4353-4359.
2. Luo J, Sharma N, Seftor EA, De Larco J, Heidger PM, Hendrix MJC, Lubaroff DM. Heterogeneous expression of invasive and metastatic properties in a prostate tumor model. Pathol Oncol Res 1997;3:264-271.
3. Presnell SC, et al. Isolation and characterization of propagable cell lines (HUNC) from the androgen-sensitive Dunning R3327H rat prostatic adenocarcinoma. Carcinogenesis 1998;19: 585-590.
4. Voigt W, Feldman M, Dunning WF. 5alpha-dihydrotestosterone-binding proteins and androgen sensitivity in prostatic cancers of Copenhagen rats. Cancer Res 1975;35:1840-1846.
5. Smolev JK, Heston WD, Scott WW, Coffey DS. Characterization of the Dunning R3327H prostatic adenocarcinoma: an appropriate animal model for prostatic cancer. Cancer Treat Rep 1977; 61:273-287.
6. Isaacs T, Yu GW, Coffey DS. The characterization of a newly identified, highly metastatic variety of Dunning R 3327 rat prostatic adenocarcinoma system: the MAT LyLu tumor. Invest Urol 1981;19:20-23.
7. Kadmon D, Heston WD, Fair WR. Treatment of a metastatic prostate derived tumor with surgery and chemotherapy. J Urol 1982;127:1238-1242.
8. Diamond DA, Barrack ER. The relationship of androgen receptor levels to androgen responsiveness in the Dunning R3327 rat prostate tumor sublines. J Urol 1984;132:821-827.
9. Isaacs JT, Isaacs WB, Feitz WF, Scheres J. Establishment and characterization of seven Dunning rat prostatic cancer cell lines and their use in developing methods for predicting metastatic abilities of prostatic cancers. Prostate 1986;9:261-281.
10. Isaacs JT, Hukku B. Nonrandom involvement of chromosome 4 in the progression of rat prostatic cancer. Prostate 1988;13:165-188.
11. Ichikawa T, et al. Localization of metastasis suppressor gene(s) for prostatic cancer to the short arm of human chromosome 11. Cancer Res 1992;52:3486-3490.
12. Minagawa H, et al. Properties of two sublines derived from rat prostatic adenocarcinoma (Dunning R 3327 tumor). Gann 1983; 74:524-533.
13. Haq M, Goltzman D, Tremblay G, Brodt P. Rat prostate adenocarcinoma cells disseminate to bone and adhere preferentially to bone marrow-derived endothelial cells. Cancer Res 1992;52: 4613-4619.
14. Geldof AA, Rao BR. Prostatic tumor (R3327) skeletal metastasis. Prostate 1990;16:279-290.
15. Newhall KR, Isaacs JT, Wright GL Jr. Dunning rat prostate tumors and cultured cell lines fail to express human prostate carcinoma-associated antigens. Prostate 1990;17:317-325.
16. Garde SV, Sheth AR, Porter AT, Pienta KJ. A comparative study on expression of prostatic inhibin peptide, prostate acid phosphatase and prostate specific antigen in androgen independent human and rat prostate carcinoma cell lines. Cancer Lett 1993; 70:159-166.
17. Ichikawa T, Ichikawa Y, Isaacs JT. Genetic factors and metastatic potential of prostatic cancer. Cancer Surv 1991;11:35-42.
18. Dong JT, et al. KAI1, a metastasis suppressor gene for prostate cancer on human chromosome 11p11.2 [see comments]. Science 1995;268:884-886.
19. Gao AC, Lou W, Dong JT, Isaacs JT. CD44 is a metastasis suppressor gene for prostatic cancer located on human chromosome 11p13. Cancer Res 1997;57:846-849.
20. Yoshida BA, et al. Mitogen-activated protein kinase kinase 4/stress-activated protein/Erk kinase 1 (MKK4/SEK1), a prostate cancer metastasis suppressor gene encoded by human chromosome 17. Cancer Res 1999;59:5483-5487.
21. Kuramochi H, et al. Suppression of invasive ability of highly metastatic rat prostate cancer by introduction of human chromosome 8. Prostate 1997;31:14-20.
22. Luu HH, et al. Identification of a novel metastasis-suppressor region on human chromosome 12. Cancer Res 1998;58:3561-3565.
23. Mashimo T, et al. Human chromosome 16 suppresses metastasis but not tumorigenesis in rat prostatic tumor cells. Cancer Res 1998;58:4572-4576.
24. Gao AC, et al. Suppression of the tumorigenicity of prostatic cancer cells by gene(s) located on human chromosome 19p13.1-13.2. Prostate 1999;38:46-54.
25. Mohler JL, et al. Detection of candidates for cancer cell motility inhibitory protein in the Dunning adenocarcinoma model. Clin Exp Metastasis 1995;13:474-480.
26. Evans CP, Walsh DS, Kohn EC. An autocrine motility factor secreted by the Dunning R-3327 rat prostatic adenocarcinoma cell subtype AT2.1. Int J Cancer 1991;49:109-113.
27. Blount LV, Cooke DB III. Point mutations in the Ki-ras2 gene of codon 12 in the Dunning R-3327 prostatic adenocarcinoma system. Prostate 1996;28:44-50.
28. Partin AW, et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res 1993;53:744-746.
29. Partin AW, et al. Preliminary immunohistochemical characterization of a monoclonal antibody (PRO:4-216) prepared from human prostate cancer nuclear matrix proteins. Urology 1997; 50:800-808.
30. Voigt W, Dunning WF. In vivo metabolism of testosterone-3H in R-3327, an androgen-sensitive rat prostatic adenocarcinoma. Cancer Res 1974;34:1447-1450.
31. Quarmby VE, et al. Expression and localization of androgen receptor in the R-3327 Dunning rat prostatic adenocarcinoma. Cancer Res 1990;50:735-739.
32. Ellis WJ, Isaacs JT. Effectiveness of complete versus partial androgen withdrawal therapy for the treatment of prostatic cancer as studied in the Dunning R-3327 system of rat prostatic adenocarcinomas. Cancer Res 1985;45:6041-6050.
33. Fuerst J, et al. Effect of active immunization against luteinizing hormone-releasing hormone on the androgen-sensitive Dunning R3327-PAP and androgen-independent Dunning R3327-AT2.1 prostate cancer sublines. Prostate 1997;32:77-84.
34. English HF, Heitjan DF, Lancaster S, Santen RJ. Beneficial effects of androgen-primed chemotherapy in the Dunning R3327 G model of prostatic cancer. Cancer Res 1991;51:1760-1765.
35. Brandstrom A, Westin P, Bergh A, Cajander S, Damber JE. Castration induces apoptosis in the ventral prostate but not in an androgen-sensitive prostatic adenocarcinoma in the rat. Cancer Res 1994;54:3594-3601.
36. Humphries JE, Isaacs JT. Unusual androgen sensitivity of the androgen-independent Dunning R-3327-G rat prostatic adenocarcinoma: androgen effect on tumor cell loss. Cancer Res 1982; 42:3148-3156.
37. Isaacs JT, Coffey DS. Adaptation versus selection as the mechanism responsible for the relapse of prostatic cancer to androgen ablation therapy as studied in the Dunning R-3327-H adenocarcinoma. Cancer Res 1981;41:5070-5075.
38. Henry JM, Isaacs JT. Relationship between tumor size and the curability of metastatic prostatic cancer by surgery alone or in combination with adjuvant chemotherapy. J Urol 1988;139: 1119-1123.
39. Mobbs BG, Johnson IE, DeSombre ER, Toth J, Hughes A. Regulation of estrogen and progestin receptor concentrations in an experimental rat prostatic carcinoma by estrogen, antiestrogen, and progesterone. Cancer Res 1987;47:2645-2651.
40. Marks TA, Petrow V. Effect of the preestrogen 4-androstene-3,17-dion-19-al on the Dunning R3327 prostatic adenocarcinoma. Cancer Res 1983;43:3687-3690.
41. Isaacs JT. The timing of androgen ablation therapy and/or chemotherapy in the treatment of prostatic cancer. Prostate 1984;5: 1-17.
42. George DJ, et al. Sustained in vivo regression of Dunning H rat prostate cancers treated with combinations of androgen ablation and Trk tyrosine kinase inhibitors, CEP-751 (KT-6587) or CEP-701 (KT-5555). Cancer Res 1999;59:2395-2401.
43. Isaacs JT. Relationship between tumor size and curability of prostatic cancer by combined chemo-hormonal therapy in rats. Cancer Res 1989;49:6290-6294.
44. Philo R, Berkowitz AS. Inhibition of Dunning tumor growth by melatonin. J Urol 1988;139:1099-1102.
45. Rabbani SA, Gladu J, Harakidas P, Jamison B, Goltzman D. Over-production of parathyroid hormone-related peptide results in increased osteolytic skeletal metastasis by prostate cancer cells in vivo. Int J Cancer 1999;80:257-264.
46. Redding TW, Coy DH, Schally AV. Prostate carcinoma tumor size in rats decreases after administration of antagonists of luteinizing hormone-releasing hormone. Proc Natl Acad Sci USA 1982;79:1273-1276.
47. Getzenberg RH, et al. Vitamin D inhibition of prostate adenocarcinoma growth and metastasis in the Dunning rat prostate model system. Urology 1997;50:999-1006.
48. Konety BR, Schwartz GG, Acierno JS Jr, Becich MJ, Getzenberg RH. The role of vitamin D in normal prostate growth and differentiation. Cell Growth Differ 1996;7:1563-1570.
49. Pienta KJ, Isaacs WB, Vindivich D, Coffey DS. The effects of basic fibroblast growth factor and suramin on cell motility and growth of rat prostate cancer cells. J Urol 1991;145:199-202.
50. von Angerer E, Kager M, Maucher A. Antitumour activity of coumarin in prostate and mammary cancer models. J Cancer Res Clin Oncol 1994;120:14-16.
51. Maucher A, Kager M, von Angerer E. Evaluation of the antitumour activity of coumarin in prostate cancer models. J Cancer Res Clin Oncol 1993;119:150-154.
52. Joseph IB, Isaacs JT. Macrophage role in the anti-prostate cancer response to one class of antiangiogenic agents [see comments]. J Natl Cancer Inst 1998;90:1648-1653.
53. Claflin AJ, McKinney EC, Fletcher MA. The Dunning R3327 prostate adenocarcinoma in the Fischer-Copenhagen F1 rat: a useful model for immunological studies. Oncology 1977;34:105-109.
54. Tjota A, Zhang YQ, Piedmonte MR, Lee CL. Adoptive immunotherapy using lymphokine-activated killer cells and recombinant interleukin-2 in preventing and treating spontaneous pulmonary metastases of syngeneic Dunning rat prostate tumor. J Urol 1991;146:177-183.
55. Sharma N, et al. A novel immunological model for the study of prostate cancer. Cancer Res 1999;59:2271-2276.
56. Vieweg J, et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res 1995;55:2366-2372.
57. Bischof JC, et al. Cryosurgery of dunning AT-1 rat prostate tumor: thermal, biophysical, and viability response at the cellular and tissue level. Cryobiology 1997;34:42-69.
58. Tucker RD, et al. The effect of interstitial hyperthermia on the Dunning prostate tumor model. J Urol 1992;147:1129-1133.
59. Vallancien G, et al. Focussed extracorporeal pyrotherapy: experimental results. Eur Urol 1991;20:211-219.
60. Bataille N, Vallancien G, Chopin D. Antitumoral local effect and metastatic risk of focused extracorporeal pyrotherapy on Dunning R-3327 tumors. Eur Urol 1996;29:72-77.
61. Gottlieb CF, Seibert GB, Block NL. Interaction of irradiation and microwave-induced hyperthermia in the Dunning R3327G prostatic adenocarcinoma model. Radiology 1988;169:243-247.
62. Peschke P, et al. Differential sensitivity of three sublines of the rat Dunning prostate tumor system R3327 to radiation and/or local tumor hyperthermia. Radiat Res 1998;150:423-430.
63. Chapelon JY, et al. In vivo effects of high-intensity ultrasound on prostatic adenocarcinoma Dunning R3327. Cancer Res 1992; 52:6353-6357.
64. Debus J, Spoo J, Jenne J, Huber P, Peschke P. Sonochemically induced radicals generated by pulsed high-energy ultrasound in vitro and in vivo. Ultrasound Med Biol 1999;25:301-306.
65. Oosterhof GO, Cornel EB, Smits GA, Debruyne FM, Schalken JA. Influence of high-intensity focused ultrasound on the development of metastases. Eur Urol 1997;32:91-95.
66. Joon DL, et al. Supraadditive apoptotic response of R3327-G rat prostate tumors to androgen ablation and radiation. Int J Radiat Oncol Biol Phys 1997;38:1071-1077.